Abstract
A highly sensitive ultra-high pressure liquid chromatography (UHPLC-MS/MS) method for estimation of paclitaxel in rat plasma has been validated. The chromatographic separation was achieved using isocratic mobile phase, consisting of acetonitrile–2mM ammonium acetate (70:30 v/v; 0.25 mL min-1). Docetaxel was used as an internal standard and tert-butyl methyl ether (TBME) as organic solvent for the liquid-liquid extraction. The mass spectrometer was operated in synapt mass spectrometry mode via positive electrospray ionization using the transitions m/z 854.4 → 286.1for paclitaxel, and m/z 808.3→ 527.2 as a parent ion of docetaxel (IS). The mean extraction-efficiency of QC samples was 90%. The lower limit of quantification (LLOQ) was 1.0 ng/mL. This method covered a linearity range from 1- 5000 ng/ml, with the total run time of 3.0 min. The applicability of UHPLC-MS/MS method was demonstrated and successfully applied for pharmacokinetic profiling of paclitaxel in rat plasma after oral administration.
Keywords: Paclitaxel, docetaxel, liquid-liquid extraction, tert-butyl methyl ether, oral administration, pharmacokinetic study.
Current Bioactive Compounds
Title:Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Volume: 12 Issue: 2
Author(s): Javed Ahmad, Niyaz Ahmad, Kanchan Kohli, Showkat R. Mir and Saima Amin
Affiliation:
Keywords: Paclitaxel, docetaxel, liquid-liquid extraction, tert-butyl methyl ether, oral administration, pharmacokinetic study.
Abstract: A highly sensitive ultra-high pressure liquid chromatography (UHPLC-MS/MS) method for estimation of paclitaxel in rat plasma has been validated. The chromatographic separation was achieved using isocratic mobile phase, consisting of acetonitrile–2mM ammonium acetate (70:30 v/v; 0.25 mL min-1). Docetaxel was used as an internal standard and tert-butyl methyl ether (TBME) as organic solvent for the liquid-liquid extraction. The mass spectrometer was operated in synapt mass spectrometry mode via positive electrospray ionization using the transitions m/z 854.4 → 286.1for paclitaxel, and m/z 808.3→ 527.2 as a parent ion of docetaxel (IS). The mean extraction-efficiency of QC samples was 90%. The lower limit of quantification (LLOQ) was 1.0 ng/mL. This method covered a linearity range from 1- 5000 ng/ml, with the total run time of 3.0 min. The applicability of UHPLC-MS/MS method was demonstrated and successfully applied for pharmacokinetic profiling of paclitaxel in rat plasma after oral administration.
Export Options
About this article
Cite this article as:
Ahmad Javed, Ahmad Niyaz, Kohli Kanchan, R. Mir Showkat and Amin Saima, Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/157340721202160504222440
DOI https://dx.doi.org/10.2174/157340721202160504222440 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant Agents
Current Neuropharmacology Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Current Cancer Drug Targets Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Microarray Data Analysis to Find Diagnostic Approach and Identify Families of Disease-Altered Genes Based on Rank-Reverse of Gene Expression
Current Bioinformatics Src as a Therapeutic Target in Breast Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Trends in Nanomaterials and Processing for Drug Delivery of Polyphenols in the Treatment of Cancer and Other Therapies
Current Drug Targets Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Five Common Functional Polymorphisms in microRNAs (rs2910164, rs2292832, rs11614913, rs3746444, rs895819) and the Susceptibility to Breast Cancer: Evidence from 8361 Cancer Cases and 8504 Controls
Current Pharmaceutical Design Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry A Hidden Human Proteome Signature Characterizes the Epithelial Mesenchymal Transition Program
Current Pharmaceutical Design Protein Regulators of Eicosanoid Synthesis: Role in Inflammation
Current Protein & Peptide Science Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy